Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04259086 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines
A Phase 2 study of Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines), sponsored by Revance Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 8
- Study locations
NCT04259086: Completed Phase 2 study of Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines), sponsored by Revance Therapeutics.
NCT04259086 is a Phase 2 study of Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines) that has completed, run by Revance Therapeutics. The registered enrollment target is 48 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04259086, a Phase 2 study of Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines), has completed, sponsored by Revance Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of DaxibotulinumtoxinA for injection (DAXI for injection) in the treatment of Glabellar Lines (GL), Dynamic Forehead Lines (FHL), and Lateral Canthal Lines(LCL)
Primary Outcome
The percentage of subjects achieving a score of 0 (none) or 1 (mild) in GL severity at maximum contraction (maximum frown) at Week 4 as assessed by the IGA-FWS
Interventions
- DRUG DaxibotulinumtoxinA for injection
Study Locations (8)
California
- Site 1 - Manhattan Beach
- Site 3 - San Diego
- Site 7 - Santa Monica
Florida
- Site 5 - Coral Gables
Massachusetts
- Site 2 - Chestnut Hill
New York
- Site 6 - New York
British Columbia
- Site 4 - Vancouver
Ontario
- Site 8 - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2019-12-06 |
| Est. Completion | 2020-11-02 |
| Phase | Phase 2 |
What the finished NCT04259086 record still lists
NCT04259086 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines) appearing as the primary indexed condition, and to 1 intervention - of which DaxibotulinumtoxinA for injection is the first listed.
NCT04259086 lists 8 locations in 6 states (California, Florida, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT04259086 about?
NCT04259086 is a clinical study titled "Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines". This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of DaxibotulinumtoxinA for injection (DAXI for injection) in the treatment of Glabellar Lines (GL), Dynamic Forehead Lines (FHL), and Lateral Canthal Lines(LCL)
What is the current status of trial NCT04259086?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2019-12-06. Estimated completion is 2020-11-02.
What conditions does trial NCT04259086 study?
This clinical trial studies the following conditions: Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines).
What interventions are being tested in trial NCT04259086?
The interventions under investigation include: DaxibotulinumtoxinA for injection (DRUG).
Who is sponsoring clinical trial NCT04259086?
This trial is sponsored by Revance Therapeutics, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04259086 being conducted?
This trial has 8 study locations across California, Florida, Massachusetts, New York, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04259086's enrollment target sits among peer trials
48 1265th of 2000 higher than 718 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI